Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- The use of darunavir/ritonavir monotherapy for maintenance of viral suppression has been evaluated in several trials
- In the PIVOT trial, boosted PI monotherapy (majority of patients received darunavir/ritonavir) was noninferior to continuing triple-drug antiretroviral therapy for the primary endpoint of loss of future drug options[Paton 2015]
- The MONET trial found that noninferiority of darunavir/ritonavir monotherapy to darunavir/ritonavir monotherapy plus NRTIs was not maintained for 144 weeks of therapy[Arribas 2012]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies